Healthcare [ 13/13 ] | Drug Manufacturers - Specialty & Generic [ 75/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 7, 24 | -0.04 Increased by +96.95% | -0.25 Increased by +84% |
| Nov 14, 23 | -1.48 Decreased by -23.33% | -0.04 Decreased by -3.6 K% |
| Sep 27, 23 | -0.59 Increased by +93.98% | -0.95 Increased by +37.89% |
| May 11, 23 | -1.93 Increased by +94.61% | -0.63 Decreased by -206.35% |
| Feb 21, 23 | -1.31 Increased by +85.11% | -1.6 Increased by +18.13% |
| Nov 14, 22 | -1.2 Increased by +94.5% | -3.6 Increased by +66.67% |
| Sep 27, 22 | -9.8 Increased by +34.67% | -7.4 Decreased by -32.43% |
| May 16, 22 | -35.8 Decreased by -26.95% | -8.2 Decreased by -336.59% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 22.93 M Decreased by -12.73% | -220 K Increased by +97.88% | Decreased by -0.96% Increased by +97.57% |
| Sep 30, 23 | 30.73 M Increased by +11.13% | -2.46 M Increased by +42.01% | Decreased by -7.99% Increased by +47.82% |
| Jun 30, 23 | 30.73 M Increased by +11.96% | -2.46 M Increased by +93.54% | Decreased by -7.99% Increased by +94.23% |
| Mar 31, 23 | 22.73 M Decreased by -6.06% | -5.84 M Increased by +95.83% | Decreased by -25.7% Increased by +95.57% |
| Dec 31, 22 | 26.28 M Increased by +13.64% | -10.39 M Increased by +10.03% | Decreased by -39.54% Increased by +20.83% |
| Sep 30, 22 | 27.66 M Increased by +26.3% | -4.24 M Increased by +84.79% | Decreased by -15.32% Increased by +87.95% |
| Jun 30, 22 | 27.45 M Increased by +16.89% | -38.06 M Decreased by -100.32% | Decreased by -138.65% Decreased by -71.38% |
| Mar 31, 22 | 24.2 M Increased by +79.49% | -140.25 M Decreased by -450.87% | Decreased by -579.57% Decreased by -206.91% |
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.